Generic Name and Formulations:
Citalopram (as HBr) 10mg, 20mg+, 40mg+; tabs (+scored).
Indications for CELEXA:
Initially 20mg once daily; after ≥1 week may increase to 40mg once daily. Doses >40mg/day: not recommended. Elderly (>60yrs), hepatic impairment, CYP2C19 poor metabolizers, concomitant cimetidine or other CYP2C19 inhibitors: max 20mg/day. 3rd trimester pregnant women: consider tapering dose.
Concomitant pimozide, linezolid, IV methylene blue. During or within 14 days of MAOIs; do not start an MAOI during or within 14 days of citalopram.
Increased risk of suicidality.
Increased risk of suicidal thinking and behavior in children, adolescents and young adults; monitor for clinical worsening and unusual changes. Congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent MI, uncompensated heart failure, or concomitant drugs that prolong the QT interval: not recommended; monitor ECG if therapy is considered. Correct hypokalemia, hypomagnesemia before starting and periodically monitor. Bipolar disorder. History of seizures or mania/hypomania. ECT. Monitor for serotonin syndrome; discontinue if occurs. Angle-closure glaucoma. Hepatic or severe renal impairment (CrCl <20mL/min). Volume-depleted. Avoid abrupt cessation. Reevaluate periodically. Write ℞ for smallest practical amount. Elderly. Labor & delivery. Pregnancy (Cat.C) (avoid 3rd trimester; see full labeling for effects on neonate). Nursing mothers: not recommended.
See Contraindications. Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Avoid drugs that prolong QT interval including Class 1A (eg, quinidine, procainamide) or Class III antiarrhythmics (eg, amiodarone, sotalol), antipsychotics (eg, chlorpromazine, thioridazine), antibiotics (eg, gatifloxacin, moxifloxacin), and others (eg, pentamidine, methadone, levomethadyl acetate). Avoid alcohol. Increased risk of bleeding with NSAIDs, aspirin, warfarin, and others that affect coagulation. May be potentiated by cimetidine, lithium, potent inhibitors of CYP2C19 or CYP3A4 (eg, azole antifungals). May be antagonized by carbamazepine. Increases metoprolol levels.
GI upset, dry mouth, somnolence, insomnia, increased sweating, anorexia, rhinitis, sexual dysfunction, agitation, fatigue, arthralgia, myalgia, hyponatremia (esp. elderly); dose-dependent QT prolongation.
Tabs—100; Soln—Contact supplier
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Prioritizing Rest in Hospital Settings: Poor Sleep Increases Costs, Complications, and Mortality
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- Addressing Commercial Incentives in the Medical Device Industry
- Cancer Patients Treated With Step III Opioids Often Have Sleep Disturbances
- Low Literacy Self-Management Program for Chronic Pain May Be Effective